144 related articles for article (PubMed ID: 17571172)
1. Endoscopic follow-up of positive fecal occult blood testing in the Ontario FOBT Project.
Paszat L; Rabeneck L; Kiefer L; Mai V; Ritvo P; Sullivan T
Can J Gastroenterol; 2007 Jun; 21(6):379-82. PubMed ID: 17571172
[TBL] [Abstract][Full Text] [Related]
2. Reasons For Lack of Follow-up Colonoscopy Among Persons With A Positive Fecal Occult Blood Test Result: A Qualitative Study.
Llovet D; Serenity M; Conn LG; Bravo CA; McCurdy BR; Dubé C; Baxter NN; Paszat L; Rabeneck L; Peters A; Tinmouth J
Am J Gastroenterol; 2018 Dec; 113(12):1872-1880. PubMed ID: 30361625
[TBL] [Abstract][Full Text] [Related]
3. Ontario's ColonCancerCheck: results from canada's first province-wide colorectal cancer screening program.
Rabeneck L; Tinmouth JM; Paszat LF; Baxter NN; Marrett LD; Ruco A; Lewis N; Gao J
Cancer Epidemiol Biomarkers Prev; 2014 Mar; 23(3):508-15. PubMed ID: 24443406
[TBL] [Abstract][Full Text] [Related]
4. Virtual colonoscopy, optical colonoscopy, or fecal occult blood testing for colorectal cancer screening: results of a pilot randomized controlled trial.
You JJ; Liu Y; Kirby J; Vora P; Moayyedi P
Trials; 2015 Jul; 16():296. PubMed ID: 26156248
[TBL] [Abstract][Full Text] [Related]
5. Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach.
Halm EA; Beaber EF; McLerran D; Chubak J; Corley DA; Rutter CM; Doubeni CA; Haas JS; Balasubramanian BA
J Gen Intern Med; 2016 Oct; 31(10):1190-7. PubMed ID: 27279097
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening.
Church TR; Yeazel MW; Jones RM; Kochevar LK; Watt GD; Mongin SJ; Cordes JE; Engelhard D
J Natl Cancer Inst; 2004 May; 96(10):770-80. PubMed ID: 15150305
[TBL] [Abstract][Full Text] [Related]
7. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
8. Fecal occult blood testing: people in Ontario are unaware of it and not ready for it.
Ritvo P; Myers R; Del Giudice ME; Pazsat L; Cotterchio M; Howlett R; Mai V; Brown P; Sullivan T; Rabeneck L
Can Fam Physician; 2009 Feb; 55(2):176-177.e4. PubMed ID: 19221081
[TBL] [Abstract][Full Text] [Related]
9. [Early detection of bowel cancer in occupational surveillance examinations: switching from a guaiak-based to an immunochemical fecal occult blood test].
Webendörfer S; Riemann JF
Dtsch Med Wochenschr; 2014 Jan; 139(3):79-83. PubMed ID: 24089288
[TBL] [Abstract][Full Text] [Related]
10. A population-based estimate of the extent of colorectal cancer screening in Ontario.
Rabeneck L; Paszat LF
Am J Gastroenterol; 2004 Jun; 99(6):1141-4. PubMed ID: 15180738
[TBL] [Abstract][Full Text] [Related]
11. Mailed participant reminders are associated with improved colonoscopy uptake after a positive FOBT result in Ontario's ColonCancerCheck program.
Stock D; Rabeneck L; Baxter NN; Paszat LF; Sutradhar R; Yun L; Tinmouth J
Implement Sci; 2015 Mar; 10():35. PubMed ID: 25885531
[TBL] [Abstract][Full Text] [Related]
12. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
[TBL] [Abstract][Full Text] [Related]
13. Effect of Chronic Comorbidities on Follow-up Colonoscopy After Positive Colorectal Cancer Screening Results: A Population-Based Cohort Study.
Bhatia D; Sutradhar R; Paszat LF; Rabeneck L; Singh S; Tinmouth J; Lipscombe LL
Am J Gastroenterol; 2022 Jul; 117(7):1137-1145. PubMed ID: 35333781
[TBL] [Abstract][Full Text] [Related]
14. Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008.
Choi KS; Lee HY; Jun JK; Shin A; Park EC
J Gastroenterol Hepatol; 2012 Jun; 27(6):1070-7. PubMed ID: 22004224
[TBL] [Abstract][Full Text] [Related]
15. Using physician-linked mailed invitations in an organised colorectal cancer screening programme: effectiveness and factors associated with response.
Tinmouth J; Baxter NN; Paszat LF; Rabeneck L; Sutradhar R; Yun L
BMJ Open; 2014 Mar; 4(3):e004494. PubMed ID: 24622950
[TBL] [Abstract][Full Text] [Related]
16. Trends and inequities in colorectal cancer screening participation in Ontario, Canada, 2005-2011.
Honein-AbouHaidar GN; Baxter NN; Moineddin R; Urbach DR; Rabeneck L; Bierman AS
Cancer Epidemiol; 2013 Dec; 37(6):946-56. PubMed ID: 23702337
[TBL] [Abstract][Full Text] [Related]
17. Sex is a stronger predictor of colorectal adenoma and advanced adenoma than fecal occult blood test.
Ferlitsch M; Heinze G; Salzl P; Britto-Arias M; Waldmann E; Reinhart K; Bannert C; Fasching E; Knoflach P; Weiss W; Trauner M; Ferlitsch A
Med Oncol; 2014 Sep; 31(9):151. PubMed ID: 25115743
[TBL] [Abstract][Full Text] [Related]
18. Lack of follow-up colonoscopy after positive FOBT in an organized colorectal cancer screening program is associated with modifiable health care practices.
Correia A; Rabeneck L; Baxter NN; Paszat LF; Sutradhar R; Yun L; Tinmouth J
Prev Med; 2015 Jul; 76():115-22. PubMed ID: 25895843
[TBL] [Abstract][Full Text] [Related]
19. Variation in colorectal cancer testing between primary care physicians: a cross-sectional study in Switzerland.
Braun AL; Prati E; Martin Y; Dvořák C; Tal K; Biller-Andorno N; Bulliard JL; Cornuz J; Selby K; Auer R
Int J Public Health; 2019 Sep; 64(7):1075-1083. PubMed ID: 31201428
[TBL] [Abstract][Full Text] [Related]
20. Contribution of patient, physician, and environmental factors to demographic and health variation in colonoscopy follow-up for abnormal colorectal cancer screening test results.
Partin MR; Gravely AA; Burgess JF; Haggstrom DA; Lillie SE; Nelson DB; Nugent SM; Shaukat A; Sultan S; Walter LC; Burgess DJ
Cancer; 2017 Sep; 123(18):3502-3512. PubMed ID: 28493543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
